Azacytidine

Phase 2Small molecule

AArog Pharmaceuticals, Inc.

Azacytidine is one of 238 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

237

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Germ Cell TumorActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Germ Cell TumorPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Preclinical

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Azacytidine

AArog Pharmaceuticals, Inc.

Phase 2

3 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Lymphoma

NCT05355051

Q1 2028

Phase 2Not yet recruiting

Elderly

NCT06778902

Q2 2030

Phase 2Recruiting

Azacytidine

NCT04747236

Q4 2034

PreclinicalRecruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT06694454

Clinical

Trials by Indication[1]

Lymphoma3 trials

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05355051·24 enrolled

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01004991·14 enrolled

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01120834·17 enrolled

Acute Myeloid Leukemia2 trials

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Completed·SSwiss Cancer Institute·Phase 2·NCT00739388·47 enrolled

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Completed·AArog Pharmaceuticals, Inc.·Phase 1/2·NCT02400281·28 enrolled

Relapsed or Refractory2 trials

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01861002·15 enrolled

Azacytidine Plus FLAG for Relapsed or Refractory AML

Unknown status·KKing Fahad Medical City·Phase 2·NCT02275663·37 enrolled

Myelodysplastic Syndrome2 trials

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02196857·16 enrolled

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01542684·8 enrolled

Azacytidine2 trials

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting·UUniversity of Virginia·Phase 2·NCT04747236·50 enrolled

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Unknown status·AAssistance Publique Hopitaux De Marseille·N/A·NCT02489929·35 enrolled

6 more indications

Allogeneic Stem Cell Transplantation1 trial

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Completed·—·Phase 2·NCT02017457·50 enrolled

Myelodysplastic Syndromes1 trial

5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)

Completed·UUniversità degli Studi di Brescia·Phase 2·NCT00897130·28 enrolled

Germ Cell Tumor1 trial

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT04648826

Elderly1 trial

AZA Combined with R-GemOx for Elderly DLBCL Patients

Not yet recruiting·—·Phase 2·NCT06778902·80 enrolled

Myeloid Malignancy1 trial

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Unknown status·SShenzhen Second People's Hospital·Phase 4·NCT03873311·114 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT06694454·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Azacytidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azacytidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azacytidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arog Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AArog Pharmaceuticals, Inc.

Azacytidine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q2 2030

Q4 2034

Trials by Indication[1]

Lymphoma3 trials

Acute Myeloid Leukemia2 trials

Relapsed or Refractory2 trials

Myelodysplastic Syndrome2 trials

Azacytidine2 trials

Allogeneic Stem Cell Transplantation1 trial

Myelodysplastic Syndromes1 trial

Germ Cell Tumor1 trial

Elderly1 trial

Myeloid Malignancy1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News